This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Integra LifeSciences Reports Fourth Quarter 2012 Financial Results

Constant Currency Growth of 5.7% Introduces 2013 Full-Year Guidance

PLAINSBORO, N.J., Feb. 21, 2013 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today reported its financial results for the fourth quarter ending December 31, 2012. Total revenues for the fourth quarter were $214.4 million, reflecting an increase of $10.9 million, or 5.4%, over the fourth quarter of 2011. Total revenues in the full year of 2012 were $830.9 million, reflecting an increase of $50.8 million, or 6.5%, over 2011.

Excluding the impact of currency exchange rates, revenues increased 5.7% over the fourth quarter of 2011 and 7.4% over the full year 2011.

The Company reported GAAP net income of $12.8 million, or $0.46 per diluted share, for the fourth quarter of 2012, compared to GAAP net income of $4.6 million, or $0.16 per diluted share, for the fourth quarter of 2011. The Company reported GAAP net income of $41.2 million, or $1.44 per diluted share, for the full year 2012, compared to GAAP net income of $28.0 million, or $0.95 per diluted share in 2011.

Net income for the fourth quarter of 2012, computed with the adjustments to GAAP reporting set forth in the attached reconciliation, was $22.0 million, or $0.78 per diluted share, compared to adjusted net income of $20.6 million, or $0.72 per diluted share, in the fourth quarter of 2011. Adjusted net income for the full year 2012, computed with the adjustments to GAAP reporting set forth in the attached reconciliation, was $87.2 million, or $3.06 per diluted share, compared to $82.2 million, or $2.79 per diluted share in 2011.

"We are pleased to have hit our growth objectives and the high end of the guidance we provided a year ago," said Peter Arduini, President and Chief Executive Officer. "The entire organization is focused on executing our strategy and growing the company."

1 of 9

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs